ReShape Lifesciences (RSLS) EGM 2025 summary
Event summary combining transcript, slides, and related documents.
EGM 2025 summary
23 Nov, 2025Opening remarks and agenda
Meeting reconvened to address Proposals 2 and 3, following partial adjournment on July 24, 2025.
Only Proposals 2 (asset sale) and 3 (certificate amendment for merger) were on the agenda.
Specific resolutions to be voted on
Proposal 2: Approval of the sale of substantially all assets.
Proposal 3: Approval and adoption of amendments to Article 6 of the Certificate of Incorporation in connection with a proposed merger with Vyome Therapeutics.
Board of Directors recommended voting in favor of both proposals.
Board and executive committee updates
Paul Hickey acted as Chairman, Brett Hansen as Secretary, and Christine Ren-Fielding as Inspector of Elections.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ReShape Lifesciences
- Cost cuts and margin gains offset revenue drop; survival depends on merger and asset sale.RSLS
Q2 20241 Feb 2026 - Q3 2024 revenue and margins improved, but future depends on merger and asset sale.RSLSQ3 202413 Jan 2026
- Enabling resale of 610,185 shares post-merger, with no proceeds to the company and new leadership.RSLSRegistration Filing16 Dec 2025
- IPO filing details a $50M shelf registration and transformative merger with Vyome Therapeutics.RSLSRegistration Filing16 Dec 2025
- IPO proceeds fund a merger and asset sale; new focus on immune-inflammatory therapeutics.RSLSRegistration Filing28 Nov 2025
- Registering 2.1M shares for resale, with proceeds tied to merger, asset sale, and debt repayment.RSLSRegistration Filing28 Nov 2025
- 42% cost reduction, M&A, and new patents support growth despite revenue decline.RSLSQ4 202425 Nov 2025
- Reverse merger, $9.2M net loss on $283K revenue, $5.7M raised, 15 months cash runway.RSLSQ3 202514 Nov 2025
- Revenue dropped 36.8% year-over-year as losses widened and liquidity risks remain elevated.RSLSQ2 202514 Aug 2025